Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Diseases of the Thyroid

  Free Subscription

Articles published in Clin Cancer Res

Retrieve available abstracts of 36 articles:
HTML format

Single Articles

    July 2021
  1. LUO J, Martucci VL, Quandt Z, Groha S, et al
    Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer.
    Clin Cancer Res. 2021 Jul 8. pii: 1078-0432.CCR-21-0921.
    PubMed     Abstract available

    June 2021
  2. PAPPA T, Ahmadi S, Marqusee E, Johnson HL, et al
    Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF(V600E)-driven papillary thyroid cancer patients.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0874.
    PubMed     Abstract available

    May 2021
  3. KIM J, Bradford D, Larkins E, Pai-Scherf LH, et al
    FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid cancers with RET gene mutations or fusions.
    Clin Cancer Res. 2021 May 27. pii: 1078-0432.CCR-21-0967.
    PubMed     Abstract available

    April 2021
  4. LI D, Chi Y, Chen X, Ge MH, et al
    Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
    Clin Cancer Res. 2021 Apr 8. pii: 1078-0432.CCR-20-2950.
    PubMed     Abstract available

    December 2020
  5. THAKUR S, Daley B, Millo C, Cochran C, et al
    (177)Lu-DOTA-EB-TATE, A Radiolabeled Analog of Somatostatin Receptor Type 2, for the Imaging and Treatment of Thyroid Cancer.
    Clin Cancer Res. 2020 Dec 22. pii: 1078-0432.CCR-20-3453.
    PubMed     Abstract available

    November 2020
  6. BRADFORD D, Larkins E, Mushti SL, Rodriguez L, et al
    FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions.
    Clin Cancer Res. 2020 Nov 25. pii: 1078-0432.CCR-20-3558.
    PubMed     Abstract available

    October 2020
  7. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available

    September 2020
  8. GRAY KD, McCloskey JE, Vedvyas Y, Kalloo OR, et al
    PD1 blockade enhances ICAM1-directed CAR T therapeutic efficacy in advanced thyroid cancer.
    Clin Cancer Res. 2020 Sep 4. pii: 1078-0432.CCR-20-1523.
    PubMed     Abstract available

    April 2020
  9. GHOSH C, Kumar S, Kushchayeva Y, Gaskins K, et al
    A Combinatorial Strategy for Targeting BRAF (V600E)-Mutant Cancers with BRAF(V600E) Inhibitor (PLX4720) and Tyrosine Kinase Inhibitor (Ponatinib).
    Clin Cancer Res. 2020;26:2022-2036.
    PubMed     Abstract available

    November 2019
  10. LANDA I, Pozdeyev N, Knauf JA, Haugen BR, et al
    Genetics of Human Thyroid Cancer Cell Lines-Response.
    Clin Cancer Res. 2019;25:6883-6884.

  11. GARCIA C, Cormier F, Groussin L
    Genetics of Human Thyroid Cancer Cell Lines-Letter.
    Clin Cancer Res. 2019;25:6882.

    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Response.
    Clin Cancer Res. 2019;25:6557.

  13. GOTTGENS EL, Rabold K, Span PN
    BRAF(V600E) Inhibitor Radiosensitizes Thyroid Cancer-Letter.
    Clin Cancer Res. 2019;25:6556.

    September 2019
  14. BROSE MS, Schlumbeger M, Jeffers M, Kappeler C, et al
    Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase 3 DECISION Trial.
    Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-3439.
    PubMed     Abstract available

    August 2019
  15. SCHIFF BA, McMurphy AB, Jasser SA, Younes MN, et al
    Editor's Note: Epidermal Growth Factor Receptor (EGFR) Is Overexpressed in Anaplastic Thyroid Cancer, and the EGFR Inhibitor Gefitinib Inhibits the Growth of Anaplastic Thyroid Cancer.
    Clin Cancer Res. 2019;25:4862.

    June 2019
  16. KURZROCK R, Ball DW, Zahurak ML, Nelkin BD, et al
    The VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.
    Clin Cancer Res. 2019 Jun 11. pii: 1078-0432.CCR-18-1881.
    PubMed     Abstract available

    May 2019
  17. ROBB R, Yang L, Shen C, Wolfe A, et al
    Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF(V600E) Mutant Thyroid Cancer Cells by Constraining DNA Double-strand Break Repair.
    Clin Cancer Res. 2019 May 16. pii: 1078-0432.CCR-18-3625.
    PubMed     Abstract available

    April 2019
  18. SINGH TD, Song J, Kim J, Chin J, et al
    A novel orally active inverse agonist of estrogen-related receptor gamma (ERRgamma), DN200434, a booster of NIS in anaplastic thyroid cancer.
    Clin Cancer Res. 2019 Apr 22. pii: 1078-0432.CCR-18-3007.
    PubMed     Abstract available

  19. CHIAPPETTA G, Tallini G, De Biasio MC, Pentimalli F, et al
    Retraction: FRA-1 Expression in Hyperplastic and Neoplastic Thyroid Diseases.
    Clin Cancer Res. 2019;25:2675.

    February 2019
  20. LANDA I, Pozdeyev N, Korch C, Marlow LA, et al
    Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
    Clin Cancer Res. 2019 Feb 8. pii: 1078-0432.CCR-18-2953.
    PubMed     Abstract available

    October 2018
  21. MITMAKER EJ, Tabah R, How J
    Thyroid Nodule DNA Methylation Signatures: An Important Diagnostic Annotation.
    Clin Cancer Res. 2018 Oct 16. pii: 1078-0432.CCR-18-2820.
    PubMed     Abstract available

  22. SONG YS, Kim MJ, Sun HJ, Kim HH, et al
    Aberrant thyroid-stimulating hormone receptor signaling increases VEGF-A and CXCL8 secretion of thyroid cancer cells, contributing to angiogenesis and tumor growth.
    Clin Cancer Res. 2018 Oct 12. pii: 1078-0432.CCR-18-0663.
    PubMed     Abstract available

    August 2018
  23. YIM JH, Choi AH, Li AX, Qin H, et al
    Identification of Tissue Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics.
    Clin Cancer Res. 2018 Aug 9. pii: 1078-0432.CCR-18-0841.
    PubMed     Abstract available

  24. PRETE A, Lo AS, Sadow PM, Bhasin SS, et al
    Pericytes elicit resistance to vemurafenib and sorafenib therapy in thyroid carcinoma via the TSP-1/TGFbeta1 axis.
    Clin Cancer Res. 2018 Aug 3. pii: 1078-0432.CCR-18-0693.
    PubMed     Abstract available

    July 2018
  25. XU M, Casio M, Range DE, Sosa JA, et al
    Copper Chelation as Targeted Therapy in a Mouse Model of Oncogenic BRAF-Driven Papillary Thyroid Cancer.
    Clin Cancer Res. 2018 Jul 31. pii: 1078-0432.CCR-17-3705.
    PubMed     Abstract available

    April 2018
  26. THAKUR S, Daley B, Gaskins K, Vasko VV, et al
    Metformin targets Mitochondrial Glycerophosphate Dehydrogenase (mGPDH) to control Rate of Oxidative Phosphorylation and growth of thyroid cancer in vitro and in vivo.
    Clin Cancer Res. 2018 Apr 24. pii: 1078-0432.CCR-17-3167.
    PubMed     Abstract available

  27. POZDEYEV N, Gay L, Sokol ES, Hartmaier RJ, et al
    Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers.
    Clin Cancer Res. 2018 Apr 3. pii: 1078-0432.CCR-18-0373.
    PubMed     Abstract available

    January 2018
  28. HANNA GJ, Busaidy NL, Chau NG, Wirth LJ, et al
    Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study.
    Clin Cancer Res. 2018 Jan 4. pii: 1078-0432.CCR-17-2297.
    PubMed     Abstract available

    November 2017
  29. KRAFT IL, Akshintala S, Zhu YJ, Lei H, et al
    Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.
    Clin Cancer Res. 2017 Nov 29. pii: 1078-0432.CCR-17-2101.
    PubMed     Abstract available

    October 2017
  30. MIN IM, Shevlin E, Vedvyas Y, Zaman M, et al
    CAR T therapy targeting ICAM-1 eliminates advanced human thyroid tumors.
    Clin Cancer Res. 2017 Oct 12. pii: clincanres.2008.2017.
    PubMed     Abstract available

    June 2017
  31. IBRAHIMPASIC T, Xu B, Landa I, Dogan S, et al
    Genomic alterations in fatal forms of non-anaplastic thyroid cancer: Identification of MED12 and RBM10 as novel thyroid cancer genes associated with tumor virulence.
    Clin Cancer Res. 2017 Jun 20. pii: clincanres.1183.2017.
    PubMed     Abstract available

  32. KOTIAN S, Zhang L, Boufraqech M, Gaskins K, et al
    Dual Inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases.
    Clin Cancer Res. 2017 Jun 9. pii: clincanres.1043.2017.
    PubMed     Abstract available

    October 2016
  33. GIBSON WJ, Ruan DT, Paulson VA, Barletta JA, et al
    Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer.
    Clin Cancer Res. 2016 Oct 17. pii: clincanres.2154.2016.
    PubMed     Abstract available

  34. RAUE F, Frank-Raue K
    Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Clin Cancer Res. 2016;22:5012-5021.
    PubMed     Abstract available

    September 2016
  35. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Abstract available

    October 2015
  36. FREEMAN-KELLER M, Kim Y, Cronin H, Richards A, et al
    Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
    Clin Cancer Res. 2015 Oct 7. pii: clincanres.1136.2015.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Diseases of the Thyroid is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.